Literature DB >> 17927296

Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Peter M Haddad1, Sonu G Sharma.   

Abstract

Antipsychotic drugs can be of great benefit in a range of psychiatric disorders, including schizophrenia and bipolar disorder, but all are associated with a wide range of potential adverse effects. These can impair quality of life, cause stigma, lead to poor adherence with medication, cause physical morbidity and, in extreme cases, be fatal. A comprehensive overview of tolerability requires a review of all available data, including randomised controlled trials (RCTs), observational studies and postmarketing surveillance studies. Assessing the relative tolerability of atypical antipsychotics is hampered by the paucity of RCTs that compare these drugs head-to-head, and limited and inconsistent reporting of adverse effect data that makes cross-study comparisons difficult. Despite methodological problems in assessment and interpretation of tolerability data, important differences exist between the atypical antipsychotics in the relative risk of acute extrapyramidal symptoms (highest risk: higher doses of risperidone), hyperglycaemia and dyslipidaemia (highest risk: clozapine and olanzapine), hyperprolactinaemia (highest risk: amisulpride and risperidone), prolongation of heart rate-corrected QT interval (QTc) [highest risk: ziprasidone and sertindole] and weight gain (highest risk: clozapine and olanzapine). Sedation, antimuscarinic symptoms, postural hypotension, agranulocytosis and seizures are more common with clozapine than with other atypical antipsychotics. The variation in their tolerability suggests that it is misleading to regard the atypical antipsychotics as a uniform drug class, and also means that the term 'atypical antipsychotic' has only limited usefulness. Differences between the atypical agents in terms of efficacy and pharmacodynamic profiles also support this view. As tolerability differs between specific conventional and atypical drugs, we conclude that broad statements comparing the relative risk of specific adverse effects between 'atypical' and 'conventional' antipsychotics are largely meaningless; rather, comparisons should be made between specific atypical and specific conventional drugs. Adverse effects are usually dose dependent and can be influenced by patient characteristics, including age and gender. These confounding factors should be considered in clinical practice and in the interpretation of research data. Selection of an antipsychotic should be on an individual patient basis. Patients should be involved in prescribing decisions and this should involve discussion about adverse effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927296     DOI: 10.2165/00023210-200721110-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  182 in total

Review 1.  Prescription-event monitoring--recent progress and future horizons.

Authors:  R D Mann
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 2.  Factors which can make patients difficult to treat.

Authors:  J M Kane
Journal:  Br J Psychiatry Suppl       Date:  1996-12

3.  Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.

Authors:  D V Jeste; A Okamoto; J Napolitano; J M Kane; R A Martinez
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

4.  The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.

Authors:  A M Crawford; C M Beasley; G D Tollefson
Journal:  Schizophr Res       Date:  1997-07-25       Impact factor: 4.939

Review 5.  Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Roy H Perlis; Jeffrey A Welge; Lana A Vornik; Robert M A Hirschfeld; Paul E Keck
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

6.  The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia.

Authors:  M Brecher; I W Rak; K Melvin; A M Jones
Journal:  Int J Psychiatry Clin Pract       Date:  2000       Impact factor: 1.812

Review 7.  Post-marketing surveillance: a UK/European perspective.

Authors:  Stephen Gough
Journal:  Curr Med Res Opin       Date:  2005-04       Impact factor: 2.580

8.  Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.

Authors:  Ya-Mei Bai; Shun-Chieh Yu; Chao-Cheng Lin
Journal:  J Clin Psychiatry       Date:  2003-11       Impact factor: 4.384

Review 9.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Neuroleptic malignant syndrome induced by atypical antipsychotics.

Authors:  Debra K Farver
Journal:  Expert Opin Drug Saf       Date:  2003-01       Impact factor: 4.250

View more
  97 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Comparing retrospective reports to real-time/real-place mobile assessments in individuals with schizophrenia and a nonclinical comparison group.

Authors:  Dror Ben-Zeev; Gregory J McHugo; Haiyi Xie; Katy Dobbins; Michael A Young
Journal:  Schizophr Bull       Date:  2012-02-01       Impact factor: 9.306

Review 3.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 4.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 5.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.

Authors:  Marrit K de Boer; Stynke Castelein; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Bull       Date:  2015-02-25       Impact factor: 9.306

6.  Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report.

Authors:  Ankit Patel; Naaz Malek; Fasiha Haq; Lauren Turnbow; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2013

7.  Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.

Authors:  Mona Darwish; Mary Bond; Ronghua Yang; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

8.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 9.  Mania and mortality: why the excess cardiovascular risk in bipolar disorder?

Authors:  Dylan P Murray; Miriam Weiner; Maithri Prabhakar; Jess G Fiedorowicz
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

Review 10.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.